Webbsök sjukhusbiblioteken
 
Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients
Komihåglistan är tom
Vis
Författare/Namn
Titel
  • Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients
Anmärkning: Innehållsbeskrivning, sammanfattning
  • Colorectal cancer is one of the most common tumour types with approximately one third of the tumours located within the rectum. Rectal cancer differs somewhat from colon cancer, e.g. regarding the method of operation and the use of preoperative radiotherapy due to a tendency for local tumour recurrence. Proteolytic enzymes have been identified as key molecules in tumour invasion and metastasis, and factors within the urokinase-plasminogen activation (uPA) system have been associated with prognosis in several tumour types, including colorectal cancer. Recently, methods have been developed to analyse the soluble fraction of the plasminogen activator receptor (suPAR) in blood samples. An association between elevated suPAR levels and poor prognosis has recently been demonstrated in colorectal cancer. We have measured suPAR levels in pretreatment plasma samples from 173 rectal cancer patients in order to confirm its prognostic strength in this clinical entity. suPAR levels were determined in ethylenediamine tetraacetic acid (EDTA) plasma by a kinetic enzyme-linked immunosorbent assay (ELISA) and analysed with respect to sex, age, Dukes' stage, tumour differentiation grade and survival. In a univariate analysis, continuous suPAR plasma levels were associated with survival (P<0.001) with shorter survival among patients with high suPAR values. Patients with suPAR values within the upper quartile had significantly shorter survival (hazard ratio (HR) 2.2, 95% confidence interval (CI) 1.3-43.7, P=0.002). In a multivariate Cox analysis, increasing suPAR values predicted shorter survival independent from Dukes' stage and tumour differentiation grade with an adjusted HR of 2.2 per ng/ml suPAR (95% CI 1.2-4.0, P=0.01). This study thus confirms that measurement of suPAR in preoperative plasma samples gives independent prognostic information in rectal cancer patients, higher values being associated with shorter survival.
Ämne
Medarbetare
  • Madsen, R R Författare/medförfattare
  • Fernö, Mårten Författare/medförfattare
  • Brunner, N Författare/medförfattare
  • Bendahl, Pär-Ola Författare/medförfattare
  • Christensen, I J Författare/medförfattare
  • Johnson, A Författare/medförfattare
  • Nilbert, Mef Författare/medförfattare
Institutionsnamn
Värdpublikation
  • European journal of cancer (Oxford, England : 1990) Pergamon-Elsevier Science Ltd ISSN 0959-8049 37:4, s. 486-491 37:4<486-491
Antal i kö:
  • 0 (0)
 
*00003604nab a22003733a 4500
*00144750
*00520110208
*008080901s2001    xx ||||      |0|| 0|eng d
*0247 $a10.1016/S0959-8049(00)00422-6$2doi
*035  $a(SwePub)oai:lup.lub.lu.se:1120480
*040  $a(SwePub)lu
*042  $9SwePub
*072 7$aart$2swepub-publicationtype
*072 7$aref$2swepub-contenttype
*1001 $aFernebro, Eva$4aut$0(SwePub:)
*24510$aPrognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer patients
*5203 $8eng$aColorectal cancer is one of the most common tumour types with approximately one third of the tumours located within the rectum. Rectal cancer differs somewhat from colon cancer, e.g. regarding the method of operation and the use of preoperative radiotherapy due to a tendency for local tumour recurrence. Proteolytic enzymes have been identified as key molecules in tumour invasion and metastasis, and factors within the urokinase-plasminogen activation (uPA) system have been associated with prognosis in several tumour types, including colorectal cancer. Recently, methods have been developed to analyse the soluble fraction of the plasminogen activator receptor (suPAR) in blood samples. An association between elevated suPAR levels and poor prognosis has recently been demonstrated in colorectal cancer. We have measured suPAR levels in pretreatment plasma samples from 173 rectal cancer patients in order to confirm its prognostic strength in this clinical entity. suPAR levels were determined in ethylenediamine tetraacetic acid (EDTA) plasma by a kinetic enzyme-linked immunosorbent assay (ELISA) and analysed with respect to sex, age, Dukes' stage, tumour differentiation grade and survival. In a univariate analysis, continuous suPAR plasma levels were associated with survival (P<0.001) with shorter survival among patients with high suPAR values. Patients with suPAR values within the upper quartile had significantly shorter survival (hazard ratio (HR) 2.2, 95% confidence interval (CI) 1.3-43.7, P=0.002). In a multivariate Cox analysis, increasing suPAR values predicted shorter survival independent from Dukes' stage and tumour differentiation grade with an adjusted HR of 2.2 per ng/ml suPAR (95% CI 1.2-4.0, P=0.01). This study thus confirms that measurement of suPAR in preoperative plasma samples gives independent prognostic information in rectal cancer patients, higher values being associated with shorter survival.
*653  $aRectal cancer
*653  $aSoluble plasminogen activator receptor (suPAR)
*653  $aPrognostic marker
*653  $aMedicin
*653  $aMedicine
*7001 $aMadsen, R R$4aut$0(SwePub:)
*7001 $aFernö, Mårten$4aut$0(SwePub:)
*7001 $aBrunner, N$4aut$0(SwePub:)
*7001 $aBendahl, Pär-Ola$4aut$0(SwePub:)
*7001 $aChristensen, I J$4aut$0(SwePub:)
*7001 $aJohnson, A$4aut$0(SwePub:)
*7001 $aNilbert, Mef$4aut$0(SwePub:)
*7102 $8swe$aLunds universitet.$bMedicin.$bInstitutionen för kliniska vetenskaper, Lund.$bSektion V.$bOnkologi, Lund.$0(SwePub:lu)
*7102 $8eng$aLund University.$bFaculty of Medicine.$bDepartment of Clinical Sciences, Lund.$bDivision V.$bOncology, Lund.$0(SwePub:lu)
*7730 $tEuropean journal of cancer (Oxford, England : 1990)$dPergamon-Elsevier Science Ltd$x0959-8049$g37:4, s. 486-491$q37:4<486-491
^
Det finns inga omdömen till denna titeln.
Klicka här för att vara den första som skriver ett omdöme.
Vis
Sänd till